At the hearing, the reconstruction administrator and the Company presented the reconstruction plan. Parts of this presentation have, as previously announced, been published on the Company’s website, www.peptonicmedical.se. The court reviewed the reconstruction plan, examined the Company’s financial position, and considered comments from creditors and authorities. The Swedish Tax Agency (Skatteverket) has expressed a negative position regarding the reconstruction, which may require further dialogue before the court makes its final decision.

Peptonic Medical AB will continue to keep the market and relevant parties informed about developments in the reconstruction process in accordance with applicable regulations.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                           

Email: anna.linton@peptonicmedical.se                                                                                     

Phone: +46 70-244 92 07

About Peptonic Medical AB                                        

PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.